Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

Phase III trial data for Eylea in Diabetic Macular Oedema-Regeneron Pharma


In the Phase III VIVID-DME trial of ...

Ruconest approved by FDA for treatment of Hereditary Angioedema- Salix Pharma


Salix Pharmaceuticals, Ltd. and ...

Two Phase IV trials report data on Vyvanse for ADHD-Shire


Shire has announced top-line results ...

Phase III trial of Mekinist + Taflinar for Metastatic Melanoma halted early-GSK


GlaxoSmithKline has announced that ...

Phase III trial of AMG 416 meets endpoints in Sec. Hyperparathyroidism-Amgen


Amgen has announced that a Phase III ...

AbbVie and Shire to merge in $32 billion deal.


The Boards of AbbVie and Shire are ...

Isavuconazole filed with EU for Fungal Infections-Basilea Pharma


Basilea Pharmaceutica has submitted a ...

Recent Updates


Clinical Guidelines

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders

Management of proximal femoral fractures 2011

Crohn's disease - Management in adults, children and young people

Antibiotics for early-onset neonatal infection: Antibiotics for the prevention and treatment of early-onset neonatal infection

Medical Journals

Non-Allergic, Mastocytosis Associated Rhinitis

Change in sense of coherence (SOC) and symptoms of depression among old non-demented persons 12 months after hospitalization

Nationwide Prospective Study of Outcomes after Elective Incisional Hernia Repair

Experimental comparison of pathogenic potential of two sibling species Anisakis simplex s.s. and Anisakis pegreffii in Wistar rat

epgonline.org Social